Lisata Therapeutics, Inc. (NASDAQ:LSTA) Short Interest Update

Lisata Therapeutics, Inc. (NASDAQ:LSTA) was the target of a significant decrease in short interest in July. As of July 31st, there was short interest totaling 56,341 shares, a decrease of 56.6% from the July 15th total of 129,920 shares. Approximately 0.7% of the shares of the company are short sold. Based on an average daily volume of 155,428 shares, the days-to-cover ratio is currently 0.4 days.

Institutional Investors Weigh In On Lisata Therapeutics

A number of hedge funds have recently made changes to their positions in the company. Cerity Partners LLC acquired a new position in Lisata Therapeutics in the second quarter valued at about $32,000. Bank of America Corp DE acquired a new stake in shares of Lisata Therapeutics during the second quarter worth approximately $35,000. CIBC Bancorp USA Inc. bought a new position in shares of Lisata Therapeutics in the third quarter valued at approximately $37,000. SOL Capital Management CO bought a new position in shares of Lisata Therapeutics in the first quarter valued at approximately $61,000. Finally, Ground Swell Capital LLC boosted its holdings in shares of Lisata Therapeutics by 64.0% in the 4th quarter. Ground Swell Capital LLC now owns 38,987 shares of the company’s stock worth $73,000 after acquiring an additional 15,213 shares in the last quarter. Institutional investors and hedge funds own 8.94% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the stock. Zacks Research upgraded shares of Lisata Therapeutics to a “hold” rating in a research note on Monday, May 18th. Weiss Ratings raised shares of Lisata Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday. Finally, HC Wainwright lowered shares of Lisata Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday, May 15th. Two investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Lisata Therapeutics presently has an average rating of “Reduce” and an average price target of $15.00.

Lisata Therapeutics Stock Up 0.9%

Lisata Therapeutics stock traded up $0.01 during mid-day trading on Monday, hitting $1.10. 12,361 shares of the company were exchanged, compared to its average volume of 133,875. The business has a fifty day moving average of $2.64 and a 200 day moving average of $3.62. Lisata Therapeutics has a 1-year low of $0.99 and a 1-year high of $5.07. The company has a market capitalization of $9.91 million, a PE ratio of -0.59 and a beta of 0.88.

About Lisata Therapeutics

Lisata Therapeutics, Inc (NASDAQ: LSTA) is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for severe diseases. The company’s pipeline comprises multiple product candidates in both preclinical and clinical stages, targeting autoimmune and inflammatory conditions through immunotherapeutic and cell-based approaches.

Lisata’s research and development activities are designed to improve upon existing treatment modalities by emphasizing targeted biologics and precision cell therapies.